Rhythm Pharmaceuticals Announces Five Presentations at Espe 2024, Including New Real-World Data in Pediatric Patients With Acquired or Congenital Hypothalamic Obesity Treated With Setmelanotide
rhythm pharmaceuticals宣佈將在2024年Espe上進行五場報告，包括針對接受Setmelanotide治療的獲得性或先天性下丘腦肥胖症兒童患者的新現實世界數據
